PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29307241-5	2018	The Immunotherapeutic potential of co-administration of liposomal doxorubicin (Lip-Dox) and GSLs or glycosphingosomes was assessed by measuring cytokine levels and VEGF in the tumour tissues.	liposomal doxorubicin	79-86	vascular endothelial growth factor A	Mus musculus	164-168	
18299174-5	2008	We hypothesize that nanodrugs (i.e. Caelyx and/or Abraxane) given at the proper menstrual stage with predicted highest VEGF expression and cancer vascular permeability allow significantly increased drug retention in breast cancer, and subsequently result in the maximal cancer growth control and minimal cancer metastatic spread.	liposomal doxorubicin	36-42	vascular endothelial growth factor A	Mus musculus	119-123